Alternative Data for Prime Medicine
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 3 | Sign up | Sign up | Sign up |
| Sentiment | 92 | Sign up | Sign up | Sign up |
| Webpage traffic | 14,000 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 46 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 2,621 | Sign up | Sign up | Sign up |
| X Followers | 2,301 | Sign up | Sign up | Sign up |
| X Mentions | 24 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 190 | Sign up | Sign up | Sign up |
About Prime Medicine
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States.
| Price | $3.30 |
| Target Price | Sign up |
| Volume | 1,440,000 |
| Market Cap | $596M |
| Year Range | $1.46 - $6.67 |
| Dividend Yield | 0% |
| Analyst Rating | 75% buy |
| Industry | Biotechnology |
In the news
 |
Prime Medicine, Inc. (PRME) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptJanuary 13 - SeekingAlpha |
 |
Prime Medicine to Present at 44th Annual J.P. Morgan Healthcare ConferenceJanuary 6 - Yahoo |
|
Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Lags Revenue EstimatesFebruary 11 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 1.2M | 44M | -43M | -51M | -49M | -0.320 |
| Q2 '25 | 1.1M | 1.9M | -750,000 | -53M | -52M | -0.410 |
| Q1 '25 | 1.5M | 1.7M | 1.5M | -52M | -51M | -0.400 |
| Q4 '24 | 2.2M | 1.7M | 2.2M | -42M | -43M | -0.310 |
| Q3 '24 | 210,000 | 1.6M | 210,000 | -53M | -53M | -0.440 |
Insider Transactions View All
| CRANDELL KEITH filed to buy 6,230,300 shares at $3.3. August 1 '25 |
| ARCH Venture Fund XII, L.P. filed to buy 6,230,300 shares at $3.3. August 1 '25 |
| NELSEN ROBERT filed to buy 6,230,300 shares at $3.3. August 1 '25 |
| Alphabet Inc. filed to buy 3,262,440 shares at $3.3. August 5 '25 |
| Liu David R. filed to buy 20,240,945 shares at $2.5. July 1 '25 |
Similar companies
Read more about Prime Medicine (PRME) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews & linkedin employees.
FAQ - Prime Medicine
The Market Cap of Prime Medicine is $596M.
Currently, the price of one share of Prime Medicine stock is $3.30.
The PRME stock price chart above provides a comprehensive visual representation of Prime Medicine's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Prime Medicine shares. Our platform offers an up-to-date PRME stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Prime Medicine (PRME) does not offer dividends to its shareholders. Investors interested in Prime Medicine should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Prime Medicine are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
